A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 100
Updated:8/3/2017
Start Date:February 2015
End Date:June 1, 2017

Use our guide to learn which trials are right for you!

A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device

The aim of this study is to compare the diagnostic accuracy of two EUS-guided tissue
acquisition devices; the 25G Echotip Ultra Fine Needle Aspiration (FNA) device and the 20G
Echotip ProCore Fine Needle Biopsy (FNB) device.

Endoscopic ultrasound (EUS)-guided tissue acquisition has emerged as a valuable method to
diagnose and stage malignancies. During Endoscopic Ultrasound (EUS), tissue samples can be
obtained for pathological evaluation with different devices. Fine needle aspiration (FNA)
provides a cytological specimen. Unfortunately, in a cytological specimen, inflammatory
changes may be undistinguishable from well-differentiated dysplasia. Moreover, for neoplasms
such as lymphomas and stromal tumors, tissue architecture and cell morphology are essential
for accurate pathological assessment. Therefore, pathologists generally prefer a histological
specimen. Fine needle biopsy (FNB) has the advantage of obtaining a histological specimen,
which may lead to better diagnostic performance. However, FNB needles are stiffer and more
difficult to handle, which can complicate tissue acquisition. In addition, the superiority of
histology over cytology in EUS-guided tissue sampling has not been proven yet. For instance,
tissue, obtained by FNA and processed with the new cell-block technique, may equal the
diagnostic yield of histological tissue cores.

A recent meta-analysis suggested that 25G is the optimal FNA needle size to obtain an
adequate cytological specimen. In this study, we aim to compare the properties and merits of
a newly designed, more flexible, 20G EUS ProCore FNB device to a conventional 25G EUS-FNA
device.

Inclusion Criteria:

- Patients referred for EUS-guided tissue acquisition because of a (I) pancreatic mass
lesion or (II) lymph node

- Age > 18 years

- Written informed consent

- Lesion can be visualized with EUS and is ≥1 cm in size

Exclusion Criteria:

- Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh
frozen plasma (FFP)

- Use of anticoagulants that cannot be discontinued in order to guarantee an INR below
1.5

- Purely cystic lesions

- Previous inclusion in the current study

- Pregnancy
We found this trial at
4
sites
333 Cedar St
New Haven, Connecticut 06504
(203) 432-4771
Principal Investigator: James Farrell
Yale University School of Medicine Founded in 1810, the Yale School of Medicine is a...
?
mi
from
New Haven, CT
Click here to add this to my saved trials
Adelaide,
Principal Investigator: Nam Nguyen
?
mi
from
Adelaide,
Click here to add this to my saved trials
Irvine, California 92697
Principal Investigator: Kenneth Chang
?
mi
from
Irvine, CA
Click here to add this to my saved trials
New York, New York
Principal Investigator: Jonathan Buscaglia
?
mi
from
New York, NY
Click here to add this to my saved trials